Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature
© Elbahaie et al; licensee BioMed Central Ltd. 2009
Received: 27 August 2009
Accepted: 09 November 2009
Published: 09 November 2009
Malignant Mesothelioma is a rare primary neoplasm affecting the serosal membranes. During its relative short course, this malignant neoplasm can give local and, rarely, distant haematogenous metastases in different organs. The reported metastatic sites include liver, lung, heart, brain, thyroid, adrenals, kidneys, pancreas, bone, soft tissue, skin and lymph nodes.
We report a sixty one year-old man with a history of malignant pleural epithelioid mesothelioma treated with six cycles of Pemetrexed and Carboplatin completed 03/11/04 followed by radiotherapy to the drain site 250 Kv/TD20Gy/5F completed 13/12/2004. Then he developed multiple facial skin lesions 4 years later. These lesions were proved to be metastatic malignant sarcomatoid mesothelioma.
Mesothelioma metastases should be suspected in any known Mesothelioma patient with newly developed skin lesion.
Malignant Mesothelioma is a rare primary neoplasm affecting the serosal membranes. During its relative short course, this malignant neoplasm can give local and, rarely, distant haematogenous metastases in different organs. The reported metastatic sites include liver, lung, heart, brain, thyroid, adrenals, kidneys, pancreas, bone, soft tissue, skin and lymph nodes. The increased incidence of malignant mesothelioma and the improvement of survival rates due to the newly introduced chemotherapeutic agents bring to light the importance of studying its amended natural history.
A 61 year-old white man with known history of pleural mesothelioma on regular follow up was found to develop multiple facial skin lesions with no clinical evidence of local recurrence 4 years after the primary diagnosis.
The patient took part on the ALIMTA trial, he received 6 cycles of Pemetrexed 500 mg/m2 + Carboplatin AUC 5 day 1 every 3 weeks; the last cycle date was 03/11/04. This was followed by radiotherapy to the drain site "250 Kv/TD20 Gy/5F" completed 13/12/2004.
CT guided core biopsy from the right posterior basal pleural mass showed a thick layer of malignant epithelioid cells. A panel of immunohistochemical markers were performed and these malignant cells are positive for mesothelial markers CK5/6 and Calretinin and negative for lung cancer markers TTF-1 and CEA. Overall, these features are consistent with a malignant Mesothelioma, Epithelioid type.
Malignant Mesothelioma is a rare primary neoplasm affecting the serosal membranes with a relative increase of its incidence rate during the last decades . Most cases of mesotheliomas are related to asbestos exposure . Its incidence has been rising steadily over the past few decades . Approximately 1000 people die of mesothelioma each year in the UK, and it is predicted to rise to 3000 by the year 2020 .
Histologically, Mesothelioma is divided into epithelial, sarcomatous and mixed or biphasic subtypes. In several series epithelial type has a significantly improved prognosis compared to sarcomatous variant . The primary diagnosis of our patient was epithelioid type; then the local recurrence was also epithelioid, while the skin metastases are of sarcomatous type; which may be explained by the heterogeneous nature of the disease or the known fact that malignant cells may loose some of there differentiation when metastasis.
Systemic therapy is the only treatment option for the majority of mesothelioma patients. For many years, chemotherapy had a minimal impact on the natural history of this cancer. Countless drugs were evaluated, most of which achieved response rates below 20% and median survival of <1 year . In recent years, there has been a surge of optimism regarding systemic treatment of this disease. Several cytotoxic agents have been shown to generate reproducible responses, improve quality of life, or prolong survival in mesothelioma. Drugs with single-agent activity include pemetrexed, raltitrexed, vinorelbine, and vinflunine . The combination of pemetrexed plus cisplatin is considered the benchmark front-line regimen for this disease, based on a phase III trial in 456 patients that yielded a response rate of 41% and a median survival of 12.1 months compared to 9.3 months for single agent cisplatin . A recent large International Expanded Access Program confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaive patients with Malignant Pleural Mesothelioma, demonstrating clinically similar time to progressive disease and 1-year survival rates . Our patient received 6 cycles of Pemetrexed 500 mg/m2 +Carboplatin AUC 5 day 1 every 21 days, completed 03/11/04 with >37 months disease free survival. This long disease free survival in mesothelioma patients is rare; however this may be explained by the small disease burden on primary presentation and/or treatment received.
During its relative short course, this malignant neoplasm, independently of the therapy, can give local or distant haematogenous metastases in different organs. The reported metastatic sites include liver, lung, heart, brain, thyroid, adrenals, kidneys, pancreas, bone, soft tissue, skin and lymph nodes [8, 9].
Only small number of cases of subcutaneous metastases of malignant Mesothelioma has been reported. However, the majority of the reported cases were considered as local invasion of the disease. To our knowledge, in English language published articles, there are only 10 reported cases of pleural Mesothelioma with distant subcutaneous metastases [8, 10–17]; seven of them had metastases to the face and/or scalp. So, our case is the 11th reported pleural Mesothelioma case with a distant subcutaneous metastasis and it is the 8th case with face and/or scalp subcutaneous metastases [8, 10–14].
With the increased incidence of malignant Mesothelioma and the improvement of survival rates due to the newly introduced chemotherapeutic agents, the number of recorded distant skin metastases is likely to increase. Metastatic disease from mesothelioma should be suspected in any known mesothelioma patient who develops a new malignant skin lesion.
Written informed consent was obtained from the patient's next of kin (his widow; as the patient is deceased) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Antman K: Natural history and epidemiology of malignant mesothelioma. Chest. 1993, 103 (Suppl): 373-376. 10.1378/chest.103.4_Supplement.373S.View ArticleGoogle Scholar
- Raptopoulos V: Peritoneal mesothelioma. Crit Rev Diagn Imaging. 1985, 24: 293-PubMedGoogle Scholar
- Attanoos RL, Gibbs AR: Pathology of malignant mesothelioma. Histopathology. 1997, 30: 403-418. 10.1046/j.1365-2559.1997.5460776.x.View ArticlePubMedGoogle Scholar
- Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, Chessa L, Nicolò G, Serra M, Capaccio A: Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Research. 1993, 13: 683-689.PubMedGoogle Scholar
- Kindler HL: Systemic Treatments for Mesothelioma: Standard and Novel. Curr Treat Options Oncol. 2008Google Scholar
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21 (14): 2636-2644. 10.1200/JCO.2003.11.136.View ArticlePubMedGoogle Scholar
- Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008, 3 (7): 756-63.View ArticlePubMedGoogle Scholar
- Edstrom L, Dawson P, Kohler J, DeMester T: Malignant mesothelioma: A metastasis to the face. J Surg Oncol. 1980, 14: 251-254. 10.1002/jso.2930140310.View ArticlePubMedGoogle Scholar
- Walters K, Martinez A: Malignant fibrous Mesothelioma metastatic to brain and liver. Acta Neuropathol. 1975, 33: 173-177. 10.1007/BF00687543.View ArticlePubMedGoogle Scholar
- Beer TW, Heenan PJ: Malignant mesothelioma presenting as a lip tumor: report of two cases with one unrecognized by 166 pathologists. Am J Dermatopathol. 2007, 29 (4): 388-91. 10.1097/DAD.0b013e3180ddc88f.View ArticlePubMedGoogle Scholar
- Kanbay A, Oguzulgen KI, Ozturk C, Memis L, Demircan S, Kurkcuoglu C, Akyurek N, Kurul C: Malignant pleural mesothelioma with scalp, cerebellar, and finger metastases: a rare case. South Med J. 2007, 100 (1): 63-5.View ArticlePubMedGoogle Scholar
- Cassarino DS, Xue W, Shannon KJ: Widespread cutaneous and perioral metastases of mesothelioma. J Cutan Pathol. 2003, 30: 582-585. 10.1034/j.1600-0560.2003.00110.x.View ArticlePubMedGoogle Scholar
- Müller C, Reichrath J, Tilgen W: Disseminated cutaneous metastasis of a biphasic pleural mesothelioma. J Eur Acad Dermatol Venereol. 2008Google Scholar
- Dutt PL, Baxter JW, O'Malley FP, Glick AD, Page DLl: Distant cutaneous metastasis of pleural malignant mesothelioma. J Cutan Pathol. 1992, 19: 490-495. 10.1111/j.1600-0560.1992.tb01602.x.View ArticlePubMedGoogle Scholar
- Prieto VG, Kenet BJ, Varghese M: Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol. 1997, 19: 261-265. 10.1097/00000372-199706000-00011.View ArticlePubMedGoogle Scholar
- Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol. 2005, 48 (4): 482-4.PubMedGoogle Scholar
- Maiorana A, Giusti F, Cesinaro AM, Conti A, Rossi G: Cutaneous metastases as the first manifestation of pleural malignant mesothelioma. J Am Acad Dermatol. 2006, 54: 363-365. 10.1016/j.jaad.2005.02.046.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.